MENU
+Compare
APVO
Stock ticker: NASDAQ
AS OF
May 13, 01:09 PM (EDT)
Price
$0.34
Change
-$0.00 (-0.00%)
Capitalization
1.89M

APVO Aptevo Therapeutics Inc Forecast, Technical & Fundamental Analysis

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer... Show more

Industry: #Biotechnology
APVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for APVO with price predictions
May 12, 2025

APVO's RSI Oscillator remains in oversold zone for 10 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for APVO just turned positive on April 11, 2025. Looking at past instances where APVO's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where APVO advanced for three days, in of 215 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where APVO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for APVO entered a downward trend on May 12, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.397) is normal, around the industry mean (14.807). P/E Ratio (0.000) is within average values for comparable stocks, (65.734). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.164). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (254.778).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. APVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. APVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
APVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

APVO is expected to report earnings to fall 96.35% to -43 cents per share on May 09

Aptevo Therapeutics Inc APVO Stock Earnings Reports
Q1'24
Est.
$-0.44
Q4'23
Missed
by $11.52
Q3'23
Missed
by $21.36
Q2'23
Missed
by $53.00
Q1'23
Beat
by $1.61
The last earnings report on March 06 showed earnings per share of -1193 cents, missing the estimate of -40 cents. With 271.32K shares outstanding, the current market capitalization sits at 1.89M.
A.I. Advisor
published General Information

General Information

a provider of immunology and cancer research services

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
2401 4th Avenue
Phone
+1 206 838-0500
Employees
40
Web
https://www.aptevotherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TSLA318.3820.12
+6.75%
Tesla
AAPL210.7912.52
+6.31%
Apple
SPY582.9918.65
+3.30%
SPDR® S&P 500® ETF
GME28.050.51
+1.85%
GameStop Corp
BTC.X102812.950000-1293.406200
-1.24%
Bitcoin cryptocurrency

APVO and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, APVO has been loosely correlated with ATBPF. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if APVO jumps, then ATBPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APVO
1D Price
Change %
APVO100%
N/A
ATBPF - APVO
37%
Loosely correlated
N/A
ENLV - APVO
36%
Loosely correlated
-1.67%
KROS - APVO
32%
Poorly correlated
+0.66%
GNPX - APVO
31%
Poorly correlated
-3.26%
IBO - APVO
27%
Poorly correlated
+2.84%
More